AMGEN INC

AI Health Factor Performance Trends

Latest Insights

21 February, 2025
Amgen to Showcase Innovation and Oncology Advancements at Upcoming Industry Conferences in 2025
Read More >>
17 February, 2025
Amgen Reports Strong Q4 2024 Earnings Despite Stock Decline from Clinical Trial Setback, Maintaining Positive Outlook for 2025
Amgen Inc. (NASDAQ:AMGN) reported notable results for the fourth quarter of 2024, showcasing a robust financial performance that has implications for investors. The company's revenue soared to $9.1 bi...
Read More
16 February, 2025
Amgen Reports Strong Q4 2024 Earnings Despite Stock Decline from Clinical Trial Setback, Maintaining Positive Outlook for 2025
Amgen Inc. (NASDAQ:AMGN) reported notable results for the fourth quarter of 2024, showcasing a robust financial performance that has implications for investors. The company's revenue soared to $9.1 bi...
Read More
15 February, 2025
Amgen Reports Strong Q4 Earnings with $9.1 Billion in Revenue, Surpassing Expectations Amid Regulatory Challenges
Amgen Inc. (NASDAQ:AMGN) has reported impressive financial results for the fourth quarter of 2024, showcasing a strong performance that exceeded analyst expectations. The biotechnology giant achieved ...
Read More
14 February, 2025
Amgen Reports Strong Q4 and Full-Year Earnings Amid FDA Setbacks, Eyes Growth in Obesity Pipeline and Rare Diseases
Amgen Inc. (NASDAQ: AMGN) recently reported strong fourth-quarter earnings for 2024, showcasing total revenues of $9.1 billion — a 3% beat over expectations — and a full-year revenue increase of 19% t...
Read More

Most Read

Join Foliko Premium!

Unlock the entire library of Foliko's Generative AI Investment Research. Plus, get AI powered trading signals and stock price predictions.

Go Premium - 7 Day Free Trial

Any content provided on our website is for information purposes only. We do not provide investment advice, nor do we consider ourselves a financial institution. Seek a duly licensed professional for investment advice.